Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease

  1. Socinski, M.A.
  2. Kaye, F.J.
  3. Spigel, D.R.
  4. Kudrik, F.J.
  5. Ponce, S.
  6. Ellis, P.M.
  7. Majem, M.
  8. Lorigan, P.
  9. Gandhi, L.
  10. Gutierrez, M.E.
  11. Nepert, D.
  12. Corral, J.
  13. Ares, L.P.
Aldizkaria:
Clinical Lung Cancer

ISSN: 1938-0690,  1525-7304

Argitalpen urtea: 2017

Alea: 18

Zenbakia: 1

Orrialdeak: 68-76.e2

Mota: Artikulua

DOI: 10.1016/J.CLLC.2016.09.002 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus